This study was designed to determine whether transforming growth factor alpha (TGF alpha) protects rat gastric mucosa against ethanol-and aspirin-induced injury. Systemic administration of TGF alpha dose-dependently decreased 100% ethanol-induced gastric mucosal injury; a dose of 50 micrograms/kg delivered intraperitoneally 15 min before ethanol decreased macroscopic mucosal injury by > 90%. At the microscopic level, TGF alpha prevented deep gastric necrotic lesions and reduced disruption of surface epithelium. Pretreatment with orogastric TGF alpha (200 micrograms/kg) only partially (40%) decreased macroscopic ethanol damage. Intraperitoneal administration of TGF alpha at a dose of 10 micrograms/kg, which does not significantly inhibit gastric acid secretion, decreased aspirininduced macroscopic damage by > 80%. TGF alpha protection does not seem to be mediated by prostaglandin, glutathione, or ornithine decarboxylase-related events, as evidenced by lack of influence of the inhibition of their production. Pretreatment with the sulfhydryl blocking agent N-ethylmaleimide partially abolished (40%) the protective effect of TGF alpha. In addition, systemic administration of TGF alpha resulted in a two-fold increase in tyrosine phosphorylation of phospholipase C-gamma 1 and in a time-and dosedependent increase in levels of immunoreactive insoluble gastric mucin; these events occurred in a time frame consistent with their participation in the protective effect of TGF alpha.
Introduction
Epidermal growth factor (EGF)' protects gastric mucosa against a variety of ulcerogens (1) (2) (3) (4) . Transforming growth factor alpha (TGFa) is a polypeptide that shares with EGF structural homology (35%) (5, 6) , a common membrane receptor, i.e., TGFa/EGF receptor (TGFa/EGFr) (7) (8) (9) , and a qualitatively similar spectrum of biological activities (10) . TGFa mRNA, but not EGF mRNA, has been shown to be expressed in the normal gastric mucosa from several species, including man ( 11) . Also, TGFa mRNA and protein have been demonstrated to increase following acute injury to the rat stomach ( 12) . Whether TGFa is protective to the gastric mucosa has not been studied. The present series of experiments was designed to determine whether systemic or orogastric administration of recombinant human TGFa afforded the rat gastric mucosa protection against an acid-independent form of acute injury (100% ethanol, EtOH) or an acid-dependent form ofinjury (aspirin, ASA). In the latter case, TGFa was administered intraperitoneally at a dose that was determined not to reduce gastric acidity significantly. In addition, we explored the mechanisms by which such protection may be conferred.
Methods
Male Sprague-Dawley rats (Harlan Sprague Dawley, Inc., Indianapolis, IN) weighing 180-220 g were used. Rats were housed individually in wire mesh cages to avoid coprophagy and fasted 24 h with ad lib. access to drinking water before the experiments.
Induction ofgastric mucosal damage
EtOH-induced gastric mucosal damage was accomplished by the orogastric administration of 1 ml of 100% EtOH. Rats were killed 1 h later by cervical dislocation. Aspirin-induced gastric mucosal damage was accomplished by the orogastric administration of acetylsalicylic acid (Sigma Chemical Co., St. Louis, MO) (200 mg/ kg body wt) suspended in 1 ml of 0.15 N HCl with the addition of two drops of Tween 80 (Sigma Chemical Co.) per 10 ml to keep ASA in a homogenous suspension. Rats were killed by cervical dislocation 4 h after ASA administration.
Assessment ofdamage
Gross. Excised stomachs were opened along the greater curvature and rinsed in saline. The degree of gastric mucosal damage was evaluated by using a computerized image analysis system (IM4-152; Analytical Imaging Concepts, Inc., Irvine, CA). The damage surface area was expressed as the percentage of the total glandular area.
Microscopic. The mucosal surface of each stomach was examined for the presence of hemorrhagic and necrotic lesions. Six tissue blocks were taken from each stomach from the areas of normal-appearing gastric mucosa. Specimens were fixed in buffered formalin and stained with hematoxylin and eosin plus periodic acid-Schiff. Coded mucosal specimens were evaluated qualitatively under light microscopy by an investigator (M. Romano) unaware of the treatment. In addition, the extent of deep histological necrosis (defined as necrotic lesions penetrating into the mucosa deeper than 0.2 mm) was quantitated morphometrically in a blinded fashion with the aid of planar morphometry computer software (Southern Micro Instruments, Inc., Atlanta, GA), by measuring the length of mucosal strips and the length of necrotic lesions for each strip. Similarly, the disruption of continuity of the surface epithelium was quantitated by measuring the length ofthe mucosal strip and the length of mucosa devoid ofthe superficial epithelial layer. Results are expressed as a percentage oftotal mucosal strip length for each studied strip.
Scanning electron microscopy
Gastric mucosal specimens were fixed in 4% glutaraldehyde in 0.1 M phosphate buffer at pH 7.2. After a fixation period of 18 h, samples were dehydrated in a graded series of EtOH solutions and critically point dried by liquid CO2 substitution. Samples were mounted on aluminum stubs using silver paste and coated with palladium gold. Specimens were then examined and photographed on a Hitachi 500 scanning electron microscope at a voltage of 20 kV.
Prostaglandin E2 assay
Gastric juice. After a 24-h fast, rats were anesthetized with pentobarbital (50 mg/kg body wt intraperitoneally [i.p.]), the abdomen was opened, and a polyethylene catheter was introduced into the stomach through a small duodenal incision. The esophagus and the pylorus were ligated (the latter over the catheter). The stomach was washed three times with 2 ml ofnormal saline, and 1.5 ml of normal saline then was instilled. TGFa (200 ,g/kg) or normal saline (control) was administered i.p. and samples of the gastric contents (0.3-0.5 ml) were obtained 15, 30, and 60 min later. Samples were buffered with PBS pH 7.4, and frozen at -70'C until assayed. Later, samples were thawed, [4H21PGE2 internal standard added, and PGE2 quantified after extraction and purification using negative ion chemical ionization gas chromatography/mass spectrometry ( 13) . Results are expressed as picograms per milliliter.
Gastric mucosa. The ex vivo generation of PGE2 was determined according to described methods ( 14, 15) . The animals were killed by cervical dislocation 30 min after i.p. administration of normal saline (control) or TGFa (200 Mg/kg). The stomachs were dissected out, opened along the greater curvature, rinsed in saline, and laid flat on absorbent paper to blot excess water. A portion of the corpus mucosa was peeled off, placed in a microfuge tube, weighed (-150 mg), and chopped with fine scissors for 1 min in 1 ml of0.1 M phosphate buffer, pH 7.4. The mixture was centrifuged (Centrifuge 5415 C; Eppendorf Inc., Fremont, CA) at 14,000 rpm for 30 s, the supernatant was discarded, and 0.5 ml of buffer was added. The pellet was dislodged and the tube vortexed for 1 min at room temperature. Indomethacin (INDO) (Sigma Chemical Co.) 50 
Glutathione assay
Total GSH concentration was measured with the glutathione reductase-5,5'-dithiobis-(2-nitrobenzoic acid) recirculating assay of Tietze ( 16) . In brief, animals were killed by cervical dislocation. The stomach was opened along the greater curvature and the gastric mucosa was scraped and weighed ( -30mg). Tissue samples were homogenized in 10% TCA with a homogenizer (Polytron; Brinkmann Instruments, Inc., Westbury, NY). The homogenates were centrifuged at 1,500 gfor 15 min at 4°C and an aliquot of the supernatant was neutralized with 0.3 M NaH2PO4. Neutralized samples were diluted ( 1:10) with 0.125 M Na3PO4, 6.3 mM EDTA, pH 7.5 (stock buffer); thereafter, 150 M1 of 0.3 mM NADPH (Boehringer Mannheim Biochemicals, Indianapolis, IN), 100 Al of6 mM dithiobis-(2-nitrobenzoic acid) (Sigma Chemical Co.), an aliquot of the sample, and stock buffer to give a final vol of 1 ml were added to cuvettes and the reaction was started by adding 10 ,ul of glutathione reductase (-50 U/ml) (Sigma Chemical Co. 
Gastric secretion
Under ether anesthesia, the pylorus was ligated and the abdomen was closed. TGFa ( 1-100 Mg/kg) or normal saline was then injected i.p. 1 h after treatment, the animals were killed by cervical dislocation, the esophagus was ligated, and the stomach dissected out. Gastric juice was collected in graduated test tubes, its volume measured to the nearest 0.1 ml, and acid concentration determined by titration with 0.01 N NaOH to pH 7. The values are expressed in milliequivalents per liter (meq/ liter) (acid concentration) and microequivalents per hour (Meq/h) (acid output).
Determination of tyrosine phosphorylation of phospholipase C-gamma 1 (PLC-,yJ) The method has been described previously ( 17) . Scraped gastric mucosa was ground in a Polytron homogenizer (Brinkman Instruments, Inc.) on ice in hypotonic buffer (20 mM Hepes, pH 7.4, 5 mM EGTA, 1 mM MgCI2, 1 mM PMSF, and 1 Mg/ml aprotinin, pepstatin, and leupeptin), centrifuged at 1,000 g for 10 min at 4VC, and the pellet discarded. A membrane fraction was obtained by centrifuging the supernatant at 100,000 g for 30 min at 4VC. The particulate membrane fraction was solubilized in a buffer containing 1% Triton X-100, 50 mM Hepes, pH 7.5, 50 mM NaCl, 50 mM NaF, 5 mM EDTA, 1 mM Na orthovanadate, 1 mM PMSF, and 1 Mg/ml aprotinin, pepstatin, and leupeptin. The supernatant cytosolic fractions from the ultracentrifugation were concentrated by lyophilization, reconstituted in the same buffer, and stored at -80°C until further use. For Western blots, membrane and cytosolic fractions ( 170 Mg) from gastric mucosa were subjected to 7% SDS-PAGE, transferred to nitrocellulose, and then incubated with a 1:500 dilution of the PLC-y antiserum followed by '251I-donkey anti-rabbit IgG (-200,000 cpm/ml; Amersham Corp., Arlington Heights, IL). The immunodetected PLC-1 bandswere visualized by autoradiography. For phosphotyrosine immunoprecipitation, a known amount of cytosolic protein (2 mg) from tissue extracts in a buffer containing phosphatase and protease inhibitors (see above), was absorbed onto 200 Ml of a Sepharose-linked antiphosphotyrosine (monoclonal 1G2) bead matrix ( 18) for 2-4 h at 4°C with rocking as described ( 19) . After washing, the specifically absorbed phosphotyrosine proteins were eluted with 20 mM phenylphosphate, electrophoresed, and subjected to PLC-,y I immunoblot. To assess the specificity of the antiphosphotyrosine matrix, the tissue cytosols were immunoprecipitated with the antiphosphotyrosine matrix in the presence ofexcess phenylphosphate or phosphotyrosine before elution and PLC-' I immunoblot. Protein was determined using the method described by Bradford (20 well above the reaction mixture. The reaction was stopped by the addition of 0.1 ml of 30% TCA; after an additional 30-60 min to collect residual radiolabeled C02, the filters were added to scintillation fluid and counted in a liquid scintillation counter. Aliquots of the 30,000 g supernatant were assayed for total protein, using the method described by Bradford (20) . Results are expressed as picomoles 14CO2 released per hour per milligram protein (pmol/h per mg).
Determination ofgastric insoluble mucin
Adherent (insoluble) gastric mucin was gently removed from the gastric mucosa using a glass slide. PBS ( 1 ml) then was added and samples were stored frozen (-70'C) until assayed. Insoluble mucin was determined by an ELISA as described previously (22) . In brief, 100 ul of mucin-containing sample was mixed with 100 Ml ofgastric mucin antibody in an Eppendorf tube (Brinkmann Instruments, Inc., Westbury, NY) and allowed to bind to equilibrium overnight at 370C. At the same time, purified gastric mucin was added to each well of a 96-well plate (500 ng/well) and allowed to bind overnight. The next day the 96-well plate was rinsed with PBS three times and 300 Ml of0.5% crystalline grade BSA was added to each well and incubated for I h at 370C. Each well was then washed with a "wash buffer" (PBS containing 0.05% Tween 20) three times and 75 Ml ofmucin-antibody mixture was added to the 96-well plate and incubated for 1 h at 370C. Each well was rinsed again with wash buffer (three times) and 100 ,l of biotinylated goat-anti-rabbit antibody (at a dilution of 1:2,000 in PBS containing 0.05% Tween 20) was added to each well and incubated for 1 h. Each well was rinsed again three times and incubated with 200 M1 of streptavidin-horseradish peroxidase at a concentration of 625 ng/ml in PBSTween, pH 6.5 for 1 h. Each well was rinsed five times with wash buffer and color was developed using 2,2'-azinobis (3-ethylbenzthiazoline-6-sulfonic acid) (0.01 g/25 ml) in 100 mM sodium citrate buffer, pH 4 
Experimental design
The experimental design is described in detail in the figure legends.
Statistical analysis
Results are expressed as mean±SEM. Significance of differences was assessed by Student's t test or analysis of variance followed by Duncan multiple range test (23) as appropriate. Differences were considered statistically significant if P was < 0.05. Data which were expressed as percentage of control were analyzed before being normalized versus control.
Results
Effect ofTGFa on EtOH-orASA-induced damage. Orogastric administration of 100% EtOH is a well-characterized animal model that yields a reproducible degree of gastric mucosal injury (24, 25) . This experimental model was selected because induction of mucosal injury is independent of luminal acidity (24, 26) . As such, this model is able to test the gastric mucosal protective ability ofthe drug studied. Pretreatment with TGFa (200 Mg/kg intraperitoneally [i.p.]) provided nearly complete protection against gross mucosal injury to the rat glandular stomach (Fig. 1) . TGFa administered i.p. at doses between 25 and 200,Mg/kg dose-dependently decreased gastric mucosal injury induced by EtOH (r = -0.88, P < 0.05) (Fig. 2) , as quantitated by computerized image analysis. TGFa (200,g/kg) decreased EtOH injury by more than 90% either when administered as a single pretreatment or when administered in four equally divided injections (Fig. 2) . Pretreatment with TGFa (25 Ag/kg or 50 ,g/kg) exerted a higher protective effect than that achieved by the same total dose given in repeated injections before and after EtOH (78 and 91% ) protection vs 27 and 63% protection, respectively (Fig. 2) .
Unlike EtOH injury, ASA-induced gastric mucosal damage is acid dependent (27) , i.e., the higher the acidity, the greater the damage. Fig. 7 A. EtOH induced complete disruption of the superficial epithelium and caused necrosis in the upper region ofthe gastric glands (Fig. 7 B) . In contrast, the gastric mucosa appeared to be well preserved ifrats were pretreated with TGFoe (200 ug/kg i.p.) 30 min before EtOH challenge (Fig. 7 C) . These sections were taken from areas that appeared grossly normal. The extent of disrupted surface epithelium and deep mucosal necrosis was quantified by planar morphometry in a blinded fashion and expressed as percentage of total mucosal strip length ( Fig. 8 ; see Methods). Surface epithelial disruption was partially reduced by TGFa (22.4%±0.7 vs 47.1%±5.2 in controls, P < 0.01 ) (Fig. 8) . In addition, pretreatment with TGFa significantly reduced EtOH-induced deep necrosis (2.9%±vs13.2%±1.9 in controls, P < 0.01). Fig. 9 (A-C) shows the scanning electron microscopy of normal rat gastric mucosa (Fig. 9 A) and ofEtOH-injured mucosa from saline-pretreated (Fig. 9 B) and TGFa-pretreated rats (Fig. 9 C) . Once again, samples were taken from areas which appeared normal upon gross examination. In control animals, EtOH caused severe disruption of the surface epithelium that resulted in formation of areas of denuded lamina propria (Fig. 9 B) . Pretreatment with TGFa (200 ,g/kg) partially prevented EtOH injury to the superficial epithelium (Fig.  9C) .
Effect of systemic TGFa on tyrosine phosphorylation of PLC-,yl. We considered whether the protection afforded by TGFa was mediated through activation ofthe TGFa/EGFr in the gastric mucosa. We studied the effect of systemic TGFa on tyrosine phosphorylation of PLC-,y 1, a putative substrate for the TGFa/EGFr (28, 29) . Cytosolic and membrane fractions of scraped gastric mucosa were examined for PLC--y 1 by Western blot analysis. The cytosolic fractions contained the majority of PLC-y 1 (Fig. 10 A) (data related to membrane fractions are not shown). To detect the tyrosine phosphorylation species of PLC-,y 1, 2 mg of cytosolic protein was absorbed onto phos- photyrosine-Ab matrix, eluted with phenylphosphate, and PLC-'y1 examined by Western blot analysis. TGFa (200 Ag/ kg) caused a time-dependent increase in tyrosine phosphorylation of PLC-y 1 in the gastric mucosa (Fig. 10 B) . At 15 min, there was a twofold increase in tyrosine phosphorylation of PLC-y 1, as assessed by measurement ofrelative optical density (data not shown). These findings were confirmed in two additional experiments (data not shown). Thus systemic administration of TGFa results in a biochemical event in the gastric mucosa linked to postreceptor signaling that occurs in a time frame consistent with its participation in TGFa-mediated gastric protection.
Role ofendogenous prostaglandin in TGFa protection. We next examined possible mechanisms by which TGFa might exert its protective effect. Prostaglandins are considered to play a role in the ability of the gastric mucosa to resist different forms ofinjury (24) . TGFa (200 ,g/kg) did not increase PGE2 release into the gastric juice nor did it increase gastric tissue levels of PGE2 (Fig. 11 A) , as assessed by mass spectrometry. Also, TGFa was not able to counteract INDO-induced depletion of PGE2 in the gastric mucosa (Fig. 11 B) . To further explore the role ofendogenous prostaglandins in TGFa protection, we studied whether pretreatment with INDO (5 mg/kg), a concentration which decreases PGE2 content ofthe rat gastric mucosa by > 70% (Fig. 11 B) , was able to prevent TGFainduced protection. INDO caused a slight increase in EtOH-induced injury, but this did not reach statistical significance (Fig.  12) . Pretreatment with INDO did not abolish the protective effect of TGFa (Fig. 12) . Role of ornithine decarboxylase activity in TGFa protection. Recently, an increase in ODC activity has been shown to be associated with the ability of EGF to protect rat gastric mucosa against stress-induced injury (30) . TGFa (100 gg/kg) administered i.p. increased ODC activity in the rat gastric mucosa from 14.7±2.7 to 22.0±4.0 pmol/h per mg. The ODC inhibitor difluoromethylorinthine (DFMO), at a concentration that decreased basal ODC activity by 65% (P < 0.01 ) and counteracted TGFa-stimulated increase in ODC activity (5 1% inhibition, P < 0.01), did not prevent the protective effect of TGFa (Fig. 13) . Thus TGFa-induced gastric mucosal protec- (Fig. 14 B) .
To assess further the role of endogenous sulfhydryl compounds in TGFa-mediated protection, we studied whether the sulfhydryl group alkylator N-ethylmaleimide (NEM) counteracted TGFa's protective effect. Fig. 15 shows that NEM (10 mg/kg), a concentration which did not significantly increase TGFa (200 ,g/kg) was administered i.p. 15 min to 6 h before EtOH administration. The damaged area in the control group is 25.9%±4.0 ofthe total glandular area. Mean±SE of(n) rats per each study group. **P < 0.001 vs control.
significantly affected EtOH-induced mucosal injury by increasing the damage to the glandular area from 20.4%±2.1 to 34.7%±6.4(P<0.05) (Fig. 15) . NEM(10and20mg/kg)did not affect glutathione tissue levels (data not shown).
Effect ofTGFa on gastric insoluble (adherent) mucin. We also examined the effect ofTGFa on levels ofgastric mucin. In these studies, the gastric mucosa was scraped lightly with a glass slide at the indicated times, and mucin levels determined by a reverse ELISA with an antibody that recognizes biologically active, insoluble gastric mucin (22) . The gastric mucosa was intact microscopically after light scraping of both TGFa and normal saline-treated rats (data not shown). TGFa (100 gg/ kg) time-dependently increased gastric insoluble mucin (Fig.  16 A) . At 15 and 30 min from TGFa administration, there was a 7.3-fold (P < 0.001 vs control) and 14.5-fold (P < 0.001 vs control) increase in adherent mucus, respectively (Fig. 16 A) . TGFa (1-100 ,gg/kg) increased gastric adherent mucin in a dose-dependent manner (r = 0.987, P < 0.05) (Fig. 16 B) . Discussion EGF protects gastric mucosa against damage induced by ASA ( 1, 2), cysteamine (3), EtOH (4, (35) (36) (37) , and stress (30) . EGF is localized mainly in submandibular salivary glands and in Brunner's glands (38, 39) . Induction of a novel EGF-secreting cell lineage has been shown adjacent to ulcerated human gastrointestinal mucosa (40) ; however, it is controversial whether EGF is expressed in the normal gastric mucosa (11, 38, 39, (41) (42) (43) . TGFa is a 50-amino acid polypeptide (44) which shares with EGF structural homology (5, 6), a common receptor (7) (8) (9) and a nearly identical spectrum ofbiological activity (10) . In particular, both EGF and TGFa stimulate proliferation of gastric epithelial cells in vitro (45) and inhibit gastric acid secretion in vitro (46) (47) (48) and in vivo (49, 50) . Unlike EGF, TGFa has been demonstrated to be expressed in the normal gastric mucosa of different species, including man and rat (11, 43, 51) . Also, immunoreactive TGFa is present in the normal human stomach in significantly higher levels than immunoreactive EGF (43) . Recently, TGFa mRNA and protein have been shown to increase after acute gastric injury in the rat ( 12) , thus suggesting a role for TGFa in gastric mucosal repair. Whether TGFa is able to prevent different forms of injury to the gastric mucosa has not been studied. Therefore, we evaluated the effect of TGFa on EtOH-or ASA-induced damage to the rat gastric mucosa.
Systemic administration of TGFa prevented EtOH injury in a dose-dependent manner and decreased EtOH-induced gross mucosal damage by > 90% (Fig. 2) . A single pretreatment with systemic TGFa was as effective as repeated administration (Fig. 2) . At the microscopic level, pretreatment with TGFa prevented by > 75% deep gastric mucosal necrosis and reduced by > 50% disruption of surface epithelium induced by EtOH (Fig. 8) . We also evaluated whether orogastric TGFa exerted any protective effect against EtOH injury. TGFa (50 ,gg/kg), a dose that affords a > 90% protection when administered systemically, did not significantly prevent EtOH injury.
At an oral dose of200 Ag/kg, TGFa provided only 40% protection to the rat gastric mucosa against EtOH-induced damage (Fig. 5) . It remains controversial whether the TGFa/EGFr, which has been demonstrated to be located on the basolateral membrane of target cells, is also expressed on the cell surface (52) (53) (54) . Systemic EGF inhibits gastric acid secretion in rats while orogastric EGF does not (55) . Likewise, serosal, but not luminal EGF, inhibits acid secretion from guinea pig gastric mucosa mounted in Ussing chambers (46) . Moreover, it is well known that acidic pH impairs the binding ofTGFa to its receptor (8, 56) . Therefore, we speculate that the partial protection obtained with orogastric administration ofTGFa reflects a systemic effect secondary to the absorption of TGFa with subsequent delivery to TGFa/EGFr located on the basolateral membrane.
ASA-induced gastric mucosal damage is dependent on the pH ofgastric contents (the more acid, the more damage) (27) , whereas EtOH injury is not (24, 26) . Therefore, to rule out the influence of gastric acid inhibition on protection, we used a concentration of TGFa ( 10 ggg/kg) that did not significantly affect gastric secretion (Fig. 3) . Moreover, ASA was suspended in 0.15 N HCl (pH = 1.02). TGFa (10 ,ug/kg) decreased acidified ASA-induced damage by > 80% (Fig. 4) . Repeated administration of TGFa (10 ,ug/kg) (30 min before and 1, 2, and 3 h after ASA) did not show any significant improvement in gastric mucosal protection as compared to a single injection of TGFa (10 ,ug/kg) 30 min before ASA administration. Therefore, TGFa is able to protect the gastric mucosa from a necrotizing agent such as EtOH whose damaging effect is acid independent and, in a non-antisecretory dose, from ASA-induced injury that is acid-dependent. Thus, TGFa may be considered a true gastric mucosal protective agent.
We did not directly compare the gastric mucosal protective ability of TGFa and EGF. However, previous studies have shown that mouse EGF (100 ,ug/kg) given orogastrically or parenterally only partly reduces the mucosal damage caused by absolute EtOH (35, 37) . Also, recombinant human EGF (30 ag/kg) has recently been shown not to exert any protective effect when given 6 h before 50% EtOH (4) . On the contrary, in our study, a 50% protective effect against EtOH injury was still seen 6 h after i.p. administration of TGFa (Fig. 6 ). These previous studies, if corroborated, suggest that TGFa, even though acting through the same receptor as EGF, seems more efficient that EGF in gastric mucosal protection. This is not altogether surprising, since several quantitative differences have been observed in the biological activity of TGFa and EGF (10) . For example, TGFa has been shown to be more potent than EGF in inducing angiogenesis in hamster cheek pouches (58) . Also, TGFa is more effective than EGF in increasing regional blood flow in the anesthetized dog (59) and in stimulating osteoclast precursor cells (60) . These quantitative differences may, in part, be explained by differential processing of the ligand-receptor complexes (61 ) . Thus far, no distinct TGFa receptor has been identified. However, to examine the comparative protective effects of TGFa and EGF more rigorously, we are presently comparing the effect of recombinant human forms of TGFa and EGF on EtOH-and ASA-induced damage to the rat gastric mucosa.
Levels of endogenous rat TGFa protein have been measured by a sensitive and specific rat RIA in the gastric mucosa and juice as well as in the plasma (14.4±4.8 pg/hg DNA, 0.3±0.1 total ng, 88 pg/ml, respectively) (Dempsey, P. J., and R. J. Coffey, unpublished observations). 15 min after i.p. administration of TGFa (50 ug/kg), plasma levels of human TGFa were 12±2.0 ng/ml, as determined by a human TGFa RIA that does not recognize rat TGFa (Dempsey, P. J., and R. J. Coffey, unpublished observations). Therefore, the doses used in this study are pharmacological ones. This must, however, be tempered by the realization that the effective concentration of the endogenously produced TGFa at the cell surface might be far greater than that measured in the gastric tissues or plasma.
The biological effects of TGFa are mediated through binding to the TGFa/ EGFr (62) . Accumulating evidence indicates that PLC-,y lisa substrate for the tyrosine kinase ofthe TGFa/ EGFr (28, 29) . The present study demonstrates for the first time in vivo in nonneoplastic tissues that systemic administration of TGFa results in a time-dependent increase in tyrosine phosphorylated PLC-y 1 (Fig. 10) . Additional biological relevance of this finding derives from the observation by Konda et al. in which prostaglandin protection of isolated guinea pig chiefcells against EtOH has been shown to be via an increase in diacylglycerol (63) , which is derived from the PLC-,y1-induced breakdown ofthe phosphoinositide (64) , thus implicating activation of PLC--y 1 as a mediator of gastric protection.
Prostaglandins are known to play in important role in the protection of gastric mucosa (24) . Therefore, we studied whether TGFa protection might be mediated by endogenous prostaglandins. TGFa, at a protective concentration, did not stimulate PGE2 production by the rat gastric mucosa nor did it counteract the INDO-induced depletion in gastric PGE2 (Fig.   1 1) . Furthermore, TGFa protection was not prevented by pretreatment with INDO in a concentration which decreased gastric tissue levels by > 70% PGE2 (Fig. 12) . Therefore, TGFa, like EGF (1, 2), does not seem to protect gastric mucosa through stimulation of endogenous prostanoid synthesis. A PGE, analogue (i.e., misoprostol) recently has been demonstrated to be effective in preventing ASA-induced injury to the human gastric mucosa (65) and approved by the FDA specifically for use in the prevention of nonsteroidal antiinflammatory drug-induced gastric mucosal damage. The observation that TGFa, at a non-antisecretory dose, protects the gastric mucosa against ASA-induced damage and appears to act independently of prostaglandins, leads us to suggest that TGFa might prove of use, alone or in combination with a prostaglandin derivative, to attenuate gastric injury induced by nonsteroidal antiinflammatory drugs (66) .
Recently, protection by EGF against stress-induced gastric lesions in the rat has been shown to be mediated in part by an increase in the activity of ODC (30) , the rate-limiting enzyme in the biosynthesis of polyamines (67) , which also play a role in gastric mucosal protection (68) . Pretreatment with TGFa caused a 1.5-fold increase in ODC activity in the gastric mucosa. However, DFMO, a specific and irreversible inhibitor of ODC (69) , at a concentration which significantly inhibited basal as well as TGFa-stimulated ODC activity, did not counteract the protective effect of TGFa (Fig. 13) . Therefore, it is unlikely that the protective effect ofTGFa is mediated through an ODC-related pathway.
Sulfhydryl compounds protect gastric mucosa against damage induced by different ulcerogens in vivo (31) (32) (33) and in vitro (70) . In particular, glutathione, the most abundant thiol in cells (34) , has been shown to play an important role in gastric mucosal protection (71) (72) (73) , even though this has been questioned by other authors (74) . Our study indicates that TGFa does not stimulate glutathione synthesis in the rat gastric mucosa nor does it prevent the depletion of glutathione gastric tissue levels induced by phorone (Fig. 14) . However, pretreatment with the sulfhydryl group alkylator NEM, at a concentration which did not increase EtOH injury, partially (40%) prevented TGFa-induced protection (Fig. 15) . NEM, at a concentration that significantly increased EtOH injury, almost completely (76%) abolished the protective effect of TGFa (Fig. 15) . or through a protein-bound, sulfhydryl-sensitive metabolic pathway (75) . However, the possibility exists that the reversal of TGFa protection by NEM is caused by an increase in the microvascular permeability which renders the gastric mucosa more vulnerable to the damaging effect of EtOH (76) .
In the attempt to elucidate further the mechanism ofTGFa protection, we studied the effect of TGFa on insoluble (adherent) gastric mucin. TGFa dose-and time-dependently stimulated adherent gastric mucus (Fig. 16 ). At 15 min from TGFa administration, there was a sevenfold increase in insoluble mucin, which is consistent with the time frame of TGFa-induced mucosal protection. However, the role of gastric mucus as a protective barrier on the gastric mucosa is controversial (77) (78) (79) NS TGFa NS TGFa may act as a dilutional barrier to damaging agents, may delay and/or restrict further damage induced by acid and pepsin, and may accelerate early reparative events. An alternate mechanism by which mucin might protect the gastric mucosa is through its ability to scavenge toxic oxygen metabolites (82) which are generated by EtOH and ASA (83) . The rapid increase in mucin levels is likely caused by release of preformed mucin. Studies are underway to examine the effect ofTGFa on rat gastric mucin mRNA expression and protein production.
In conclusion: (a) systemic TGFa protects the rat gastric mucosa against EtOH-induced microscopic and macroscopic injury; (b) this protective effect is seen also with ASA-induced gastric injury at non-antisecretory concentrations ofTGFa; (c) this protection does not seem to be mediated by prostaglandin, Figure 14 . with a significant increase in adherent gastric mucin.
